Recital 41, Regulation (EU) 2026/1826

In forcesince 28 Jul 2026

The application for the renewal of the approval of the active substance amisulbrom was submitted on 28 September 2021 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 28 April 2023 that it had assessed the admissibility of the application pursuant to Article 8 of Implementing Regulation (EU) 2020/1740, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority, which conducted a public consultation on it between 15 February and 15 April 2024, pursuant to Article 10 of Implementing Regulation (EU) 2020/1740. The rapporteur Member State has not finalised the risk assessments pursuant to Article 11 of Implementing Regulation (EU) 2020/1740 and could not provide estimates of when it would be able to submit the draft renewal assessment report to the Commission and the Authority. As additional time is necessary to complete the remaining steps in the renewal procedure, the duration of the extension of the approval period should be set at 42 months, until 15 March 2030.